Comparative Pharmacology
Head-to-head clinical analysis: MODAFINIL versus QUILLICHEW ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MODAFINIL versus QUILLICHEW ER.
MODAFINIL vs QUILLICHEW ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The precise mechanism of action is unknown. Modafinil is a wakefulness-promoting agent that may have direct or indirect effects on dopamine, norepinephrine, serotonin, GABA, glutamate, and orexin systems. It binds to the dopamine transporter and inhibits dopamine reuptake.
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
200 mg orally once daily in the morning.
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
None Documented
None Documented
Clinical Note
moderateArmodafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil."
Clinical Note
moderateModafinil + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Modafinil."
Clinical Note
moderateModafinil + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Modafinil."
Clinical Note
moderateModafinil + Erythromycin
Terminal elimination half-life is approximately 15 hours (range 10–30 hours). This supports once-daily dosing for sustained wakefulness.
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For QuilliChew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Primarily renal (as metabolites and unchanged drug); approximately 80% of the dose is recovered in urine, with less than 10% as unchanged modafinil. Fecal excretion accounts for less than 1%.
QuilliChew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant
"The metabolism of Erythromycin can be decreased when combined with Modafinil."